Introduction
Over 32 million individuals are currently infected with HIV-1 worldwide, and 1.2 million within the United States. In most developed countries, the availability of a combination of effective antiretroviral medicines has significantly increased life expectancy. As a chronic disease, HIV has lead to a host of new challenges. Perhaps the most common is HIV-associated neurocognitive disorder (Antinori et al., 2007) , which may affect between 40% and 70% of infected individuals (McArthur et al., 2005) . Prior to the availability of combination antiretroviral therapy (cART), neurological illness in HIV+ individuals often presented as dementia (i.e., HIV-associated dementia, or HAD), with an acute encephalitis as the frequent underlying cause. A key aspect of the neuropathogenic process of HAD is the phenotypic modification of peripheral blood monocytes and their subsequent migration across the blood brain barrier (Pulliam et al., 1997) . CD16+ monocytes are among the first cells to become infected with HIV. This subset of cells expands in HIV and Simian immunodeficiency virus (SIV) infection (Thieblemont et al., 1995; Otani et al., 1998) , and also appears to be associated with the pathogenesis of milder HIV-associated neurocognitive Journal of Neuroimmunology 265 (2013) 96-105 
